STRATEC Biomedical AG / Key word(s): Quarter Results/Interim Report
STRATEC reports on first nine months of 2013
Birkenfeld, October 30, 2013
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announced its results for the period from January 1, 2013 to September 30, 2013 upon the publication of its Interim Report as of September 30, 2013.
* 2012 figure adjusted for a one-off item of EUR 3.3 million due to an income-neutral reclassification from unfinished services and prepayments received upon the write-down of a development project. On an unadjusted basis, sales for the first nine months of 2012 amounted to EUR 87.6 million and the corresponding EBIT margin amounted to 15.3%.
The EBIT margin for the first nine-months amounted to 14.8%, compared to 15.8% in the equivalent period in 2012. In H1 2012 we saw strong business performance with service parts resulting in an EBIT margin of 17.1%, before an uncharacteristically sharp decline in H2 2012. Since the beginning of 2013, demand has continued to improve in this segment and order volatility has slightly declined. Consequently, the share of sales from service parts has recovered to a higher level compared to an extraordinary fourth quarter 2012. The EBIT margin for the third quarter alone amounted to 16.2%, compared to 13.4% for Q3 2012, driven mainly by this recovery in service parts year-on-year.
Earnings per share amounted to EUR 0.90 in the period under report, compared with EUR 0.93 in the previous year.
Alongside a major new development and supply agreement signed in the first quarter of 2013, a further contract is now in the final agreement stage. Both projects are expected to make notable contributions to STRATEC's sales growth from the 2015 and 2016 financial years respectively.
Planning reliability in the global diagnostics industry is currently affected by a number of uncertainties, such as government savings measures, high unemployment in important market regions, and healthcare system reforms. Particularly the healthcare reforms in the USA will not be without consequences. According to statements made by several partners, the negative implications of the persistently high pressure on prices expected at laboratories and hospitals are likely to be offset by the increase in test volumes also expected due to the marked rise in the number of people insured.
Our ability to forecast developments continues to be impeded by several other external factors, such as capacity utilization rates at installed systems, the timing of further market launches, the planned production launches for new systems, further consolidation in the IVD market, and macroeconomic market factors.
Further details can be found in our Interim Report as of September 30, 2013 published at www.stratec.com > STRATEC Group > Investors > Financial Reports.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
End of Corporate News
30.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
|End of News||DGAP News-Service|